GSK plc ADRhedged
GSKH
New York Stock Exchange Arca73.28
USD
-1.21
- -
GSK plc ADRhedged
GSKH
(New York Stock Exchange Arca)
Recent
price
73.28
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Precidian ETFs Trust - GSK plc ADRhedged (GSKH) is an exchange-traded fund that seeks to deliver investment results corresponding generally to the total return of GSK plc ordinary shares in its local market, before fees and expenses, by mitigating embedded currency exposure through a combination of American Depositary Receipts (ADRs) and currency hedging contracts. The fund, under normal circumstances, invests at least 95% of its net assets in unsponsored ADRs of GSK plc, a UK-listed multinational pharmaceutical company focused on prescription medicines including its ViiV HIV joint venture with Pfizer and Shionogi, and vaccines such as Shingrix for shingles; it pairs these Portfolio Securities with a daily-adjusted currency swap contract to hedge fluctuations between the British pound and the U.S. dollar, providing U.S. investors with local currency returns net of expenses without direct investment in the underlying company. Shares trade on the NYSE Arca exchange. GSK plc ADRhedged operates within the healthcare sector, specifically the pharmaceuticals sub-industry, targeting investors seeking single-company exposure to international equities with currency risk mitigation; its portfolio is non-diversified, with over 97% allocation to GSK plc, resulting in heightened concentration risk tied to the company's performance in drug development, regulatory approvals, and global health markets. The fund maintains cash or cash equivalents for currency hedge settlements and marks the swap to market daily, exposing it to counterparty, liquidity, and imperfect hedging risks. Precidian ETFs Trust, managed by Precidian Funds LLC and headquartered in the United States, specializes in innovative ETF structures like the ActiveShares method; the GSKH series forms part of a broader suite of ADRhedged ETFs covering companies across Europe, Asia, and other regions. Recent developments include the fund's transition to NYSE Arca as its principal listing exchange, effective April 23, 2025, replacing prior references to Cboe BZX Exchange, Inc., as detailed in a prospectus supplement dated April 16, 2025. Launched amid Precidian Investments' expansion of its ADRhedged product line, GSKH remains active as of October 27, 2025, with ongoing portfolio monitoring to ensure availability of English-language material information on GSK plc via public sources. No major acquisitions, funding rounds, or strategic shifts specific to the series were reported in the last 1-2 years, though the prospectus framework supports potential future additions to the trust's series portfolio.